Radiosynthesis of microtubule‐targeted theranostic methyl N‐[5‐(3’‐radiohalobenzoyl)‐1H‐benzimidazol‐2‐yl]carbamates

Microtubules are a target for a broad spectrum of drugs used as chemotherapeutics to treat hematological malignancies and solid tumors. Most of these drugs have significant dose‐limiting toxicities including peripheral neuropathies that can be debilitating and permanent. In an ongoing effort to develop safer and more effective drugs, benzimidazole‐based compounds are being developed as replacement for vincristine and similar agents. In this report, we describe radiosyntheses of novel microtubule‐targeting methyl N‐5‐(3’‐radiohalobenzoyl)‐1H‐benzimidazol‐2‐yl]carbamates 4 that are intended as potential imaging agents and molecular radiotherapeutics. ¹²⁵I‐ and ¹³¹I‐radiolabeled derivatives were prepared either by direct radioiodination of methyl N‐(6‐benzoyl‐1H‐benzimidazol‐2‐yl)carbamate 1 or radioiododestannylation of the corresponding stannane precursor 3 . The direct radioiodination was conducted in a solution of 1 in triflic acid and produced after ~1 hour at elevated temperatures and HPLC purification on average 62% of the no‐carrier added products ¹²⁵I‐ 4 and ¹³¹I‐ 4 . Radioiododestannylation of 3’‐trimethylstannane 3 proceeded with ease at room temperature in the presence of H₂O₂ as the oxidant and produced no‐carrier‐added ¹²⁵I‐ 4 and ¹³¹I‐ 4 in high isolated yields, on average 85%. The radiohalodestannylation protocol is universal and can be applied to other radiohalides including ¹²⁴I to produce ¹²⁴I‐ 4 , a positron emission tomography agent, and ²¹¹At to produce ²¹¹At‐ 4 , an α‐particle emitting radiotherapeutic.